OncoMatch/Clinical Trials/NCT07318675
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Is NCT07318675 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HW211026 for actinic keratosis (ak).
Treatment: HW211026 — This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage OLSEN GRADE 1, OLSEN GRADE 2 (Olsen)
Olsen grade 1 or 2
Prior therapy
Cannot have received: systemic drug therapy for actinic keratosis
Cannot have received: topical intervention for actinic keratosis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07318675 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic drug therapy for actinic keratosis, topical intervention for actinic keratosis disqualifies patients from enrollment.
What disease stage is eligible?
Stage OLSEN GRADE 1 or OLSEN GRADE 2 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify